At the Supreme Court on Monday, there were signs that the pharmaceutical industry could end up on the losing side of a case with serious implications for medicine and drug prices.
The case in question focused on the Obama administration’s rules for a new process to review patents. Drug makers, supporting the plaintiffs, are urging the court to change that process, which right now makes it easier to invalidate the patents that are crucial to their business.
But the plaintiffs seemed to be at a disadvantage before the court.
Read Full Article »